Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Veru Inc (VERU)

Veru Inc (VERU)
0.5400 x 19 0.5426 x 49
Post-market by (Cboe BZX)
0.5427 +0.0182 (+3.47%) 04/11/25 [NASDAQ]
0.5400 x 19 0.5426 x 49
Post-market 0.5426 -0.0001 (-0.02%) 19:26 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.5061
Day High
0.5456
Open 0.5100
Previous Close 0.5245 0.5245
Volume 765,600 765,600
Avg Vol 2,227,380 2,227,380
Stochastic %K 19.19% 19.19%
Weighted Alpha -33.58 -33.58
5-Day Change -0.0271 (-4.76%) -0.0271 (-4.76%)
52-Week Range 0.4500 - 1.8500 0.4500 - 1.8500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,443
  • Shares Outstanding, K 146,384
  • Annual Sales, $ 16,890 K
  • Annual Income, $ -37,800 K
  • EBIT $ -37 M
  • EBITDA $ -37 M
  • 60-Month Beta -0.69
  • Price/Sales 4.55
  • Price/Cash Flow N/A
  • Price/Book 2.88
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.29
  • Most Recent Earnings $-0.07 on 02/13/25
  • Next Earnings Date 05/14/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.070 on 04/28/14
  • Sector Medical
  • INDUSTRY GROUPING Medical Products

Options Overview Details

View History
  • Implied Volatility 200.67% ( +54.23%)
  • Historical Volatility 106.21%
  • IV Percentile 23%
  • IV Rank 19.99%
  • IV High 787.37% on 03/06/25
  • IV Low 54.07% on 10/21/24
  • Put/Call Vol Ratio 2.43
  • Today's Volume 247
  • Volume Avg (30-Day) 3,469
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 71,884
  • Open Int (30-Day) 66,137

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.07
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4500 +20.60%
on 03/14/25
Period Open: 0.4938
0.7300 -25.66%
on 04/02/25
+0.0489 (+9.90%)
since 03/11/25
3-Month
0.4500 +20.60%
on 03/14/25
Period Open: 0.7818
1.4200 -61.78%
on 01/24/25
-0.2391 (-30.58%)
since 01/10/25
52-Week
0.4500 +20.60%
on 03/14/25
Period Open: 1.7900
1.8500 -70.66%
on 04/12/24
-1.2473 (-69.68%)
since 04/11/24

Most Recent Stories

More News
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

VERU : 0.5427 (+3.47%)
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

VERU : 0.5427 (+3.47%)
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

VERU : 0.5427 (+3.47%)
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

VERU : 0.5427 (+3.47%)
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

VERU : 0.5427 (+3.47%)
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

VERU : 0.5427 (+3.47%)
Veru Inc. to Present at 17th International Conference on Sarcopenia, Cachexia, & Wasting Disorders

Veru Inc. will present on improving GLP-1 RA weight loss drugs at an upcoming conference in Washington, DC.Quiver AI SummaryVeru Inc. has announced its participation in the 17th International Conference...

VERU : 0.5427 (+3.47%)
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

VERU : 0.5427 (+3.47%)
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

VERU : 0.5427 (+3.47%)
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

VERU : 0.5427 (+3.47%)

Business Summary

Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.5963
2nd Resistance Point 0.5710
1st Resistance Point 0.5568
Last Price 0.5427
1st Support Level 0.5173
2nd Support Level 0.4920
3rd Support Level 0.4778

See More

52-Week High 1.8500
Fibonacci 61.8% 1.3152
Fibonacci 50% 1.1500
Fibonacci 38.2% 0.9848
Last Price 0.5427
52-Week Low 0.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar